<DOC>
	<DOCNO>NCT00628212</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety determine appropriate dose phase 3 confirmatory trial , MP-513 ( Teneligliptin ) patient type 2 Diabetes base change HbA1c adverse event 12 week administration daily multi-center , randomize , double-blind , placebo-controlled , parallel assignment manner .</brief_summary>
	<brief_title>Efficacy Safety Study MP-513 Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients 20 75 year old Patients dietary management take therapeutic exercise diabetes 12 week administration investigational drug Patients whose HbA1c 6.5 9.5 % Patients administer drug prohibit concomitant use within 12 week administration investigational drug . Patients type 1 diabetes , diabetes mellitus cause pancreas failure , secondary diabetes ( Cushing disease , acromegaly , etc ) Patients Class III/IV heart failure symptom accord New York Heart Association ( NYHA ) functional classification Patients serious diabetic complication Patients habitual excessive alcohol consumption . Patients severe hepatic disorder severe renal disorder . Pregnant , lactating , probably pregnant patient , patient agree contraception</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>insulin resistance</keyword>
</DOC>